REPLY: “From Cloud to Edge” Research Predicts the Rise of Edge Computing and Unveils the Main Trends in the Cloud Computing Market
2.2.2021 12:00:00 EET | Business Wire | Press release
By 2025 Cloud Computing will lead the ICT infrastructure market and Edge Computing will become an exponentially growing market, according to Reply’s new research “From Cloud to Edge”, made possible by Reply’s Trend SONAR proprietary data-driven platform and the support of Teknowlogy Group.
The research explores the use of both Cloud Computing and Edge Computing technologies in “Europe-5” (Italy, Germany, France, Netherlands, Belgium), and “Big-5” (USA, United Kingdom, Brazil, China, India) clusters in order to understand the evolution of the market.
In the next 5 five years Edge Computing will be an exponentially growing market in all “Europe-5” and “Big-5” clusters’ countries. Germany will be the biggest European market for both Cloud Computing and Edge Computing; the USA will be the dominant market worldwide.
The growing usage of IoT solutions, the closer combination of Information Technology and Operational Technology and the integration of Industrial Control Systems in the IT stack, as well as future 5G campus solutions for low-latency applications, are accelerating the need for edge solutions.
In fact, Edge Computing can support companies with computing tasks that cannot be done in the cloud and offers clear advantages when dealing with low latency, connectivity, security or privacy and transmitted data volumes are an issue.
Edge and distributed cloud architectures will increase the speed of data processing and reduce time lag. Edge computing, alone or in combination with Cloud Computing, will play a key role to enable technologies like autonomous vehicles, digital factories, smart cities, digital health, smart tracking and much more.
Hybrid models like Edge Cloud will be pushed by the hyperscalers and the wide 5G rollout will give Telcos and their service partners a relevant role in the new ecosystem, especially thanks to mobile-edge computing which is able to ensure very low latency without local infrastructure, with compute units not on-premise but extremely close from to a cell tower.
“Edge computing is here to stay. It is already starting to reshape enterprise computing and it can play a vital role in IT architectures. All the industries that need to perform the computing tasks as close to where data is gathered as possible will benefit from Edge Computing. At Reply, we’re already supporting global enterprises to design and implement architectures that leverage the best of Edge and Cloud Computing, while ensuring privacy and cybersecurity” commented Filippo Rizzante, CTO Reply.
In addition, the research indicates that Cloud Computing became the most popular ICT focus during Coronavirus peaks. COVID-19 has intensified the global spread of Cloud Computing technologies after 15 years of steady growth: across the world, millions of users started to use cloud-based platforms to collaborate, shop online, and for entertainment purposes.
Cloud technologies are key to being able to react and restart activities. By 2021 in both “Europe-5” and “Big-5” clusters the Infrastructure as a Service (IaaS)/Platform as a Service (PaaS) market will grow - in all scenarios - between 50% and 55% (vs. 2019).
The Software as a Service (SaaS) market is also set to grow rapidly in every country analysed. In particular, by 2025 it is predicted to double in the USA, UK and all “Europe-5” cluster countries, while likely to quadruple in India and China.
For more insights download the full research “From Cloud To Edge”.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005054/en/
Contact information
Media
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Aaron Miani
a.miani@reply.com
Tel. +44 (0)20 7730 6000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom